Compounds > iclaprim
Page last updated: 2024-09-05

iclaprim and Infections, Staphylococcal

iclaprim has been researched along with Infections, Staphylococcal in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Brown-Driver, V; Cunningham, ML; Finn, J; Hilgers, MT; Hough, G; Kwan, BP; Lam, T; Nelson, KJ; Ong, V; Shaw, KJ; Trzoss, M1
Balser, B; Corey, GR; Desplats, E; Dryden, M; File, TM; Holland, TL; Huang, DB; Lodise, T; O'Riordan, W; Torres, A; Wilcox, MH1
Micek, ST; Neuner, EA; Ritchie, DJ1
Kollef, MH1
Peppard, WJ; Schuenke, CD1

Reviews

2 review(s) available for iclaprim and Infections, Staphylococcal

ArticleYear
New antibiotics for healthcare-associated pneumonia.
    Seminars in respiratory and critical care medicine, 2009, Volume: 30, Issue:1

    Topics: Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Ceftaroline; Cephalosporins; Cross Infection; Doripenem; Glycopeptides; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Pneumonia, Bacterial; Pseudomonas Infections; Pyrimidines; Staphylococcal Infections; Teicoplanin

2009
New antimicrobial agents for methicillin-resistant Staphylococcus aureus.
    Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine, 2009, Volume: 11, Issue:4

    Topics: Aminoglycosides; Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Glycopeptides; Humans; Lipoglycopeptides; Methicillin-Resistant Staphylococcus aureus; Pyrimidines; Staphylococcal Infections; Teicoplanin

2009

Trials

1 trial(s) available for iclaprim and Infections, Staphylococcal

ArticleYear
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.
    International journal of antimicrobial agents, 2018, Volume: 52, Issue:2

    Topics: Acute Disease; Adult; Anti-Bacterial Agents; Creatinine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Patient Safety; Pyrimidines; Skin Diseases, Bacterial; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes; Treatment Outcome; Vancomycin

2018

Other Studies

2 other study(ies) available for iclaprim and Infections, Staphylococcal

ArticleYear
Structure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-diaminoquinazolines.
    Journal of medicinal chemistry, 2014, Feb-13, Volume: 57, Issue:3

    Topics: Animals; Anti-Bacterial Agents; Benzimidazoles; Drug Resistance, Bacterial; Folic Acid Antagonists; Humans; Mice; Microbial Sensitivity Tests; Models, Molecular; Quinazolines; Sepsis; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae; Structure-Activity Relationship; Tetrahydrofolate Dehydrogenase

2014
Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections.
    Current opinion in investigational drugs (London, England : 2000), 2008, Volume: 9, Issue:2

    Topics: Animals; Anti-Bacterial Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Folic Acid Antagonists; Humans; Methicillin Resistance; Molecular Structure; Patents as Topic; Pyrimidines; Staphylococcal Infections; Structure-Activity Relationship

2008